Pharma Mar S.A. Logo

Pharma Mar S.A.

Develops and commercializes marine-derived oncology treatments for rare cancers.

PHM | MC

Overview

Corporate Details

ISIN(s):
ES0169501022 (+1 more)
LEI:
959800QWKZ45ZQC2AV58
Country:
Spain
Address:
Avenida de los Reyes 1 Polígono Industrial La Mina, 28770 Colmenar Viejo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pharma Mar S.A. is an integrated biopharmaceutical company focused on the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to create novel therapies, with a particular focus on rare cancers. PharmaMar manages the entire drug development process, from research, supported by its extensive collection of over 500,000 marine invertebrate samples, to marketing. Its portfolio of approved anti-tumor drugs includes Yondelis® (trabectedin) for soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-28 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-10-24 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-10-08 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-09-22 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-06-19 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-06-18 00:00
Post-Annual General Meeting Information
Se informa que todas las propuestas de acuerdos presentadas por el Consejo a la…
Spanish 389.6 KB
2025-06-18 00:00
Investor Presentation
Se remite copia de la presentación a accionistas que será realizada en la Junta…
Spanish 2.5 MB
2025-06-09 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-06-09 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-06-05 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-05-26 17:41
Transaction in Own Shares
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa d…
Spanish 171.3 KB
2025-05-23 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-05-22 00:00
Director's Dealing
Motivo de la notificación: Persona Estrechamente Vinculada
Spanish 91.4 KB
2025-05-21 08:27
Regulatory News Service
La Sociedad presenta la solicitud en la UE para comercializar lurbinectedina en…
Spanish 744.9 KB
2025-05-19 17:40
Transaction in Own Shares
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa d…
Spanish 183.1 KB

Automate Your Workflow. Get a real-time feed of all Pharma Mar S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pharma Mar S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pharma Mar S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Eisai Co., Ltd. Logo
A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.
Japan 4523
Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden ELIC
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden ELN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel ENLV
Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden ERMA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea 183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea 446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden EQL
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France ERYP

Talk to a Data Expert

Have a question? We'll get back to you promptly.